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BACKGROUND: Although it is accepted that metastatic colorectal cancers (mCRCs) that carry activating mutations in KRAS are
unresponsive to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, a significant fraction of KRAS wild-type (wt)
mCRCs are also unresponsive to anti-EGFR therapy. Genes encoding EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are
promising gene expression-based markers but have not been incorporated into a test to dichotomise KRAS wt mCRC patients with
respect to sensitivity to anti-EGFR treatment.
METHODS: We used RT–PCR to test 110 candidate gene expression markers in primary tumours from 144 KRAS wt mCRC patients
who received monotherapy with the anti-EGFR antibody cetuximab. Results were correlated with multiple clinical endpoints: disease
control, objective response, and progression-free survival (PFS).
RESULTS: Expression of many of the tested candidate genes, including EREG and AREG, strongly associate with all clinical endpoints.
Using multivariate analysis with two-layer five-fold cross-validation, we constructed a four-gene predictive classifier. Strikingly, patients
below the classifier cutpoint had PFS and disease control rates similar to those of patients with KRAS mutant mCRC.
CONCLUSION: Gene expression appears to identify KRAS wt mCRC patients who receive little benefit from cetuximab. It will be
important to test this model in an independent validation study.
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The epidermal growth factor receptor (EGFR) has been implicated
in the growth and aggressiveness of a number of different cancers
(Mendelsohn and Baselga, 2006), several of which are responsive
to drugs that target this receptor (Baselga and Arteaga, 2005;
Modjtahedi and Essapen, 2009). The anti-EGFR monoclonal
antibody cetuximab has demonstrated clinical benefit in, and is
widely used to treat metastatic colorectal cancer (mCRC) (Jonker
et al, 2009; Van Cutsem et al, 2010). Efforts have been made to
identify biomarkers that will optimise patient selection for
treatment to maximise the therapeutic index for mCRC patients
receiving cetuximab and other anti-EGFR therapies.
Activating KRAS mutations, which are present in 30–40% of
CRC (Samowitz et al, 2000; Andreyev et al, 2001) serve as a
key useful biomarker in this context. A number of independent
studies strongly link the presence of a somatic activating mutation
in the KRAS gene (codons 12 or 13) with nearly complete
mCRC resistance to anti-EGFR monoclonal antibodies cetuximab
(Benvenuti et al, 2007; Di Fiore et al, 2007; Khambata-Ford et al,
2007; De Roock et al, 2008; Karapetis et al, 2008; Lie `vre et al, 2008)
and panitumumab (Benvenuti et al, 2007; Amado et al, 2008; Freeman
et al, 2008), leading the American Society of Clinical Oncology to
recommend that only mCRC patients with KRAS wild-type (wt)
mCRC be considered candidates to receive anti-EGFR therapy
(Allegra et al, 2009). Other investigated mutations in mCRC are
either rare (e.g., activating EGFR mutations (Barber et al, 2004;
Tsuchihashi et al, 2005)) or, as a result of conflicting data,
controversial with respect to response to anti-EGFR monoclonal
antibodies (e.g., PI3K and BRAF); (Samowitz et al, 2005;
Di Nicolantonio et al, 2008; Loupakis et al, 2009; Perrone et al,
2009; Prenen et al, 2009; Sartore-Bianchi et al, 2009; Souglakos
et al, 2009; Roth et al, 2010). Despite the significance of KRAS
mutations, the efficacy of anti-EGFR monoclonal antibodies in the
60–70% of mCRC patients with KRAS wt tumours is still limited,
with response rates between 10 and 40% (Allegra et al, 2009).
There is a need for additional predictive biomarkers for these
patients. Interestingly, the expression of the EGFR protein has not
been strongly associated with clinical response to cetuximab in
colorectal cancer (Cunningham et al, 2004; Saltz et al, 2004; Chung
et al, 2005; Meropol, 2005), although there is limited evidence that
amplification of the EGFR gene relates to objective response and
other indices of clinical benefit (Moroni et al, 2005; Cappuzzo et al,
2008; Personeni et al, 2008).
Two independent groups recently reported that increased
expression of genes encoding two EGFR ligands, amphiregulin
(AREG) and epiregulin (EREG) strongly associates with increased
therapeutic benefit from cetuximab in mCRC patients (Khambata-
Ford et al, 2007; Jacobs et al, 2009; Jonker et al, 2009). Although
these results are encouraging, a gene expression-based test with
adequate performance has not yet been developed. An expanded
model with markers additional to AREG and EREG may be
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soptimal. For practical clinical utility the test would categorise
patients for treatment, that is, have dichotomising cutpoints
(Jacobs et al, 2009).
With the goal of creating a clinically useful test, we have used
high-throughput RT–PCR to explore a set of 110 biologically
based candidate gene expression biomarkers in formalin-fixed,
paraffin-embedded primary tumour specimens from 144 KRAS wt
mCRC patients who had been treated with cetuximab mono-
therapy. There is a strong rationale for this strategy of testing
candidate genes based on the known biology of the EGFR pathway
as evidenced by the above referenced association of KRAS to drug
resistance and AREG and EREG to drug sensitivity. The fact that
constitutive activation of KRAS marks resistance to cetuximab is
consistent with the known role of KRAS as a key downstream
signal transducer of the EGFR pathway (Mendelsohn and Baselga,
2006). The findings that increased AREG and EREG expression
associate with sensitivity to cetuximab accords with the general
concept of oncogene addiction (Weinstein, 2002).
MATERIALS AND METHODS
Colorectal cancer tissue samples were obtained from the primary
colon tumours removed at initial surgical resection for patients
from three cetuximab monotherapy studies: IMC CP02-0144, IMC
CP02-0141, and BMS CA225-045. None of the tissue samples were
obtained from metastases and a single sample was obtained from
the primary tumours. Eligibility in the IMC CP02-0141 study
required that patients had previous therapy with at least one
chemotherapeutic regimen for advanced disease that included a
fluoropyrimidine and irinotecan, and documentation that their
disease was refractory to this treatment. Patients were eligible
for IMC CP02-0144 and BMS CA225-045 if their disease was
refractory to irinotecan-, oxaliplatin-, and fluoropyrimidine-based
regimens. In all three studies, eligibility criteria also included an
Eastern Cooperative Oncology Group performance status of two or
less. In addition, patients were required to be at least 18 years of
age; patients in IMC CP02-0144 and BMS CA225-045 could not
have received major surgery, radiation chemotherapy, or investi-
gational agents within 4 weeks. Study CP02-0141 also indicated
that no surgery was permitted within 21 days of study entry,
excluding previous diagnostic biopsy. Standard laboratory test
values had to be within normal limits. Patients were treated with
cetuximab at a loading dose of 400mgm
–2 followed by 250mgm
–2
weekly. In one study, patients could escalate their dose after the
first 3 weeks and every 3 weeks thereafter to a maximum dose of
400mgm
–2, if they did not experience a skin rash greater than
grade 2. All protocols were approved by institutional review boards
at the participating institutions.
RNA was extracted from a minimum of three to six 5-mm
unstained sections of FPE tumour tissue on glass slides without a
cover slip, using protocols optimised for colon FPE tissue by
Genomic Health Inc. (Redwood City, CA, USA). One slide from
each patient was H&E stained and used as a guide for removal of
non-tumour tissue by manual microdissection. RNA was isolated
and TaqMan RT–PCR was carried out as previously described
(Clark-Langone et al, 2007).
Candidate genes (shown in Supplementary Table S1) were
selected for gene expression analysis, based on previous evidence
that they may be linked to the sensitivity or resistance to EGFR-
inhibitor drugs either directly (as components of the EGFR
signaling pathway) or indirectly (by marking fundamental
pathobiological variables such as cell cycle activity, or stromal
response). As shown in Supplementary Figure S1, using the initial
set of 254 samples, expression levels of 99 genes were evaluated.
Both emerging evidence regarding the importance of KRAS
mutation status in response to EGFR inhibitors and the desire to
investigate additional cancer-related genes as well as alternative
reference genes resulted in an optimised version of the assay gene
panel. Genes significantly associated with outcome in the original
assay were carried forward to the optimised assay. Of the original
254 samples, 226 (those with sufficient RNA remaining) were re-
assayed with the updated panel of 57 genes plus KRAS sequences.
All together, 110 genes were evaluated.
A normalisation method was used to compensate for systematic
sources of variation in gene expression measurements. In the
optimised version of the assay, the cycle threshold (CT) measure-
ment for each test gene was normalised relative to the average
expression of five reference genes (UBB, ATP5E, PGK1, VDAC2,
and GPX1) in that tumour RNA sample. The reference genes were
selected for this purpose in the course of RT–PCR studies of
several hundred genes carried out in over 1800 stage II and III
colorectal cancer specimens. For details regarding the assay
formats, see Supplementary Figure S1.
Wild-type and mutant KRAS were detected using allele-specific
blocker PCR that uses a PCR primer that is specific for the mutant
template, and an oligonucleotide that blocks amplification of the
wt gene (Morlan et al, 2009). Samples were assayed for the seven
most frequent mutations reported in KRAS codons 12 and 13
(Gly12Asp, Gly12Ala, Gly12Val, Gly12Ser, Gly12Arg, Gly12Cys,
and Gly13Asp), accounting for approximately 97% of all KRAS
mutations observed in CRC.
Clinical endpoints and statistical methods
Complete response (CR), partial response (PR), stable disease
(SD), or progressive disease (PD) was assessed by study
investigators. Complete response was defined as complete
disappearance of all tumour lesions for at least 4 weeks from the
date of documentation of CR. Partial response was defined as a
decrease (relative to baseline) of 50% or greater in the sum of the
products of the two largest perpendicular diameters of all index
lesions, as determined by two observations at least 4 weeks apart.
Additionally, patients could not meet the criteria for PD.
Progressive disease was defined as at least a 25% increase in the
sum of the products of all index lesions (taking as reference the
smallest sum recorded at or following baseline) or progression of
non-measurable lesions or the appearance of any new lesions.
Stable disease was defined as failure to meet criteria for CR or
PR in the absence of PD. Disease control was defined as having
either CR, PR, or SD as a patient’s best response. Objective
response rate (ORR) was defined as the proportion of patients
achieving a CR or PR as a patient’s best response. Progression-
free survival (PFS) was defined as the time from entry onto
the study to the first date of progression for patients with
documented PD, or the date of death for patients who died within
90 days of their last tumour assessment without documented
progression. Patients who did not progress or die were censored
at the date of their last tumour assessment. Gene expression
was standardised by dividing each gene’s reference-normalised
expression level (on the log2 CT scale) by its sample s.d. Univariate
logistic regression models were used to examine the associations
between the expression of test genes and outcome (disease control
and objective response). Univariate Cox proportional hazards
regression models were used to examine the associations between
the expression of test genes or the four-gene score and PFS.
For each regression model, the P-value under the likelihood ratio
test of the null hypothesis that the odds ratio (or hazard ratio)
equals one is reported. All statistical tests are two-sided and
Po0.05 is considered significant. The minimum false discovery
rate (FDR) at which each null hypothesis could be rejected using
the method of Benjamini and Hochberg (1995) is also provided as
a conservative statistical adjustment for the multiplicity of testing
multiple gene models.
KRAS expression measurements were used to classify each
patient as either positive or negative for at least one KRAS
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smutation. Using a logistic regression model, a probability of
mutation for each KRAS mutation sequence and sample was
estimated. When the predicted probability of a mutation was 40.5,
the sample was classified as positive for the particular KRAS
mutation variant. The logistic regression model applied to these
data were developed using samples from an external training data
set in which the KRAS mutation status of each sample was known.
P-values comparing the proportion of responses (disease control
or objective response) in patients with and without KRAS
mutations were calculated using the w
2 test.
Multi-gene classification models were developed using two-
layer, five-fold cross-validation approaches in the KRAS wt subset
of patients (Ambroise and McLachlan, 2002). A supervised
approach was used, analysing only the subset of genes that were
Table 1 KRAS wild-type patients by endpoint and study
Disease control
endpoint
Objective response
endpoint
Study Responder
Non-
responder Responder
Non-
responder Total
CA 225045 12 11 5 18 23
IMCL CP02-0141 8 3 3 8 11
IMCL CP02-0144 67 43 23 87 110
Total 87
a 57
b 31
c 113
d 144
Abbreviations: CR¼complete response; PD¼progressive disease; PR¼partial
response; SD¼stable disease.
aIncludes 1 CR, 30 PR, and 56 SD.
bIncludes PD
only.
cIncludes 1 CR and 30 PR.
dIncludes 57 PD and 56 SD.
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Figure 1 (A) Distribution of likelihood ratio P-values in KRAS wt patients by gene rank (disease control). Note:  and þ¼genes significantly associated
with outcome, unadjusted P-value o0.05, ¼ genes associated with outcome controlling for FDR o0.05, *¼ genes not significantly associated with
outcome. In total, 110 genes depicted. (B) Distribution of likelihood ratio P-values in KRAS wt patients by gene rank (objective response). Note:  and þ¼
genes significantly associated with outcome, unadjusted P-value o0.05, ¼ genes associated with outcome controlling for FDR o0.05, *¼ genes
not significantly associated with outcome. In total, 110 genes depicted. (C) Distribution of likelihood ratio P-values in KRAS wt patients by gene rank (PFS).
Note:  and þ¼genes significantly associated with outcome, unadjusted P-value o0.05, ¼ genes associated with outcome controlling for FDR o0.05,
*¼ genes not significantly associated with outcome. In total, 110 genes depicted.
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sidentified as significantly associated with outcome based on
univariate analyses of gene expression and outcome (disease
control and objective response). Forward stepwise logistic regres-
sion was employed in the inner layers and inspection of the area
under the curve (AUC) for each of the models was used to identify
the optimal multi-gene model. The outer layers were used to
evaluate the models constructed in the inner layers. The two-layer,
five-fold cross-validation was repeated 50 times using different
partitions of the data, yielding 250 models. The threshold for the
final four-gene model was determined by identifying the cutpoint
that yielded the highest number of true negatives plus true
positives on the disease control endpoint. Median time to
progression and/or death was calculated using Kaplan–Meier
(product-limit estimation) methods and associated 95% confi-
dence intervals were calculated based on the sign test (Brookmeyer
and Crowley, 1982). Corresponding Kaplan–Meier plots were used
to display PFS for the selected four-gene classifier on the disease
control endpoint. The log-rank test was calculated to test the null
hypothesis that there is no difference in the probability of
progression and/or death over the entire time period among the
groups identified by the multi-gene classifier.
RESULTS
Patient characteristics
A total of 326 tumour specimens were obtained from the primary
colon tumours removed at initial surgical resection for patients
who were enrolled in cetuximab monotherapy trials. After
exclusion of 46 specimens based on predefined pathology and
laboratory criteria (10 because of insufficient tumour, 22 because
of insufficient RNA, and 14 because of laboratory failure), 280
patients had successful gene expression analysis. An additional 26
patients were clinically not evaluable (not treated, or withdrew
or died before tumour assessment), resulting in 254 patients that
were evaluable for the RT–PCR-based gene expression analysis
shown in Supplementary Figure S1. There were 226 samples with
sufficient RNA for both (KRAS) mutation and gene expression
analysis (174 patients from IMC CP02-0144, 13 patients from IMC
CP02-0141, and 39 patients from BMS CA225-045).
An activating KRAS (codons 12 or 13) mutation was identified
in 82 (36%) of the 226 patients. Both this frequency, as well as
the distribution of the individual codon 12 and 13 mutations
(Supplementary Table S2), are in accord with the published
literature (Samowitz et al, 2000). Also, consistent with published
literature, the disease control, ORR and PFS rates were very low in
patients with KRAS mutant compared with KRAS wt tumours
(Supplementary Table S3 and Supplementary Figure S2). The 144
patients with KRAS wt tumours were carried forward for gene
expression analysis.
Of the 144 patients, 1 patient (o1%) had a CR, 30 patients
(21%) had a PR, 56 patients (39%) had SD, and 57 (40%) had PD
(Table 1).
Gene expression and sensitivity to cetuximab
in KRAS wt mCRC
Among the 144 patients with wt KRAS tumours, the expression
levels of 26, 12, and 25 genes were associated with the disease
control, objective response, and PFS endpoints, respectively
(FDR o0.05 after adjusting for multiplicity). As shown by Figures
1A–C, many of these gene expression values had highly significant
P-values. Further, as shown in Figure 2, many of these genes
are associated with outcome over multiple endpoints (nine of
them across all three endpoints). These genes include DUSP6,
which encodes a dual specificity phosphatase, and EREG
and AREG, which encode the EGFR ligands epiregulin and
amphiregulin, respectively. Increased expression of DUSP6,
which blocks the EGFR pathway at MAPK, is associated with
decreased likelihood of disease control, while increased expression
of AREG and EREG, which stimulate the EGFR pathway,
are associated with increased likelihood of disease control.
Although EREG and AREG tightly co-expressed, they did not
co-express with other significant genes, consistent with the
possibility that the other genes carry independent predictive
information (see gene expression dendrogram in Supplementary
Figure S3).
Unlike AREG and EREG, genes encoding other EGFR ligands,
TGFalpha, HB-EGF, and EGF, were not consistently associated
with outcome. Our results indicate that AREG and EREG tend to
be more highly expressed than these other ligands in mCRC (see
Supplementary Figure S4).
It should be noted that not all of the highly significant genes are
known to be linked to the EGFR pathway. For example, PTP4A3,
a gene encoding a protein tyrosine phosphatase that has been
reported to be expressed at increased levels in aggressive (Mollevı ´
et al, 2008) or metastatic (Guzinska-Ustymowicz et al, 2009) CRC,
strongly associated with therapy benefit across all three endpoints
(Figure 2).
Of the three studies combined for this analysis, study IMCL
CP02-0144 accounted for 76% of the total patients (Table 1).
Results in the subset of patients from study IMCL CP02-0144 alone
were highly consistent with results obtained when analysing all
three studies combined (data not shown).
Gene
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Note: hazard ratios and odds ratios represent the effect for one standard
deviation change in gene expression.
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Figure 2 Genes associated with outcome after adjusting for multiplicity
across all three endpoints in KRAS wt patients.
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with KRAS wt mCRC
In view of the substantial fraction of tested genes whose expression
was significantly associated with each of the clinical endpoints,
we explored the potential performance of multi-gene classifiers.
Applying two-layer five-fold cross-validation in patients with
KRAS wt tumours, we identified several genes that consistently
performed well as a group based on diagnostic measures (AUC,
positive predictive value (PPV), negative predictive value (NPV),
sensitivity, and specificity) in the outer layer of the cross-
validation. We considered models with differing numbers of
genes, including a two-gene model with AREG and EREG only.
Evaluation of receiver operating characteristic curves indicated
that a two-gene model has a sharper shoulder than a four-gene
model, which implies that this model is more sensitive to the
choice of a cutpoint than the four-gene model. The additional
robustness of the four-gene model to choice of cutpoint, combined
with the desire to minimise analytical variation suggested that a
four-gene model was optimal. A final model that yields a predictive
score includes four genes: EREG, AREG, and two other genes,
DUSP6 (which encodes a dual-specificity phosphatase) and
SLC26A3 (which encodes an intestinal chloride ion transporter
that is also known as downregulated in colon adenoma).
A cutpoint in the four-gene score was selected to construct a
classifier that identifies KRAS wt patients most likely to benefit
from cetuximab treatment. The cutpoint for the four-gene model is
the maximum of the sum of the true negative and true positive
values for the disease control endpoint when the predictive
score was applied. As shown in Figure 3A, this selected cutpoint
would lead to treatment of 84 patients (58% of KRAS wt patients)
out of which 71 would have disease control (85% of these treated
patients). Sixty patients would not have been treated, 27% of whom
would have disease control (the majority (82%) of whom had SD).
When the four-gene score with the same cutpoint is applied
to objective response, 84 patients would be treated, and 28 (33%)
would respond; 60 patients would not be treated, and 3 of these (5%)
would respond (Figure 3B). With respect to both the disease control
and objective response endpoints, use of this multi-gene classifier
in addition to KRAS status significantly improves specificity
and PPV when compared with a patient selection based on KRAS
status alone, but with a slight decrease in sensitivity (Figure 3C
and D).
The performance of the four-gene classifier with respect to PFS
is shown in Figure 4. The median PFS for KRAS wt patients with a
four-gene score at or above the cutpoint is 163 days compared with
a median PFS for all KRAS wt patients of 103 days. It is noteworthy
that the 60 KRAS wt patients with a four-gene score below the
cutpoint had a median time to progression and/or death similar to
the 82 patients whose tumours carried a KRAS mutation (40 and 41
days, respectively: hazard ratio for this comparison is 1.04 (95%
CI: 0.74–1.46)). The hazard ratio for comparison of KRAS wt
patients above and below the four-gene score cutpoint is 0.22 (95%
CI: 0.15–0.32). A test of the proportional hazards assumption
indicated that the assumption was not violated (P¼0.41).
However, it should be stated that the performance of the four-
gene classifier on the PFS endpoint is evaluated here in the same
group of patients that was used to develop the classifier based on
objective response and disease control endpoints.
DISCUSSION
Here, we report that a number of candidate gene expression
markers, many of which were selected based on their relationship
to the EGFR pathway, strongly associate with disease control,
PFS and ORR in KRAS wt mCRC patients receiving monotherapy
with the anti-EGFR antibody cetuximab. Multivariate analysis
Objective response rate
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NPV
Disease control
(n=84)
No disease control
(n=60)
Objective
response=no
Objective
response=yes
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Figure 3 (A) Four-gene classification model for prediction of cetuximab benefit measured by disease control rate in KRAS wt patients. (B) Four-gene
classification model for prediction of cetuximab benefit measured by objective response rate in KRAS wt patients. (C) Performance measures of two patient
classifiers (disease control endpoint). (D) Performance measures of two patient classifiers (objective response endpoint). The four-gene classifier includes
DUSP6, SLC23A2 and the average of EREG and AREG. EREG and AREG were averaged because they tightly co-express in these colon cancer specimens
(R
2¼0.83).
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four-gene model that predicts the likelihood that individual
patients with KRAS wt mCRC will respond to cetuximab. This
model sharply dichotomises patients with respect to likelihood
of response, which has practical potential in the clinical setting.
We propose that this model is sufficiently promising that it
should be brought forward for testing in a clinical validation
study.
Two of the genes in this model, AREG and EREG, have been
previously identified as strong markers of sensitivity to anti-EGFR
antibodies: by one study that analysed metastatic mCRC tissue
from patients receiving cetuximab monotherapy (Khambata-Ford
et al, 2007), and by another study that analysed primary mCRC
tissue from patients receiving cetuximab in combination with
chemotherapy (Jacobs et al, 2009; Jonker et al, 2009). Although
AREG and EREG have not been studied in a large validation trial
with a non-treated patient arm, our results with those of the two
previous studies provide substantial evidence that these two
markers are real and robust.
To develop an optimised gene expression-based test, we have
examined additional candidate gene expression markers. The
discoveries that key regulatory genes in the EGFR pathway, in the
form of KRAS, EREG, and AREG, are anti-EGFR predictive markers
suggested to us the potential value of screening other candidate
markers based on both the biology of this pathway as well as other
features of the pathobiology of CRC. As this study examines
primary mCRC tissue from patients receiving cetuximab mono-
therapy, it is unencumbered by the potentially confounding
complication presented by combination therapy. Further, it
incorporates both a relatively large number of KRAS wt patients
and multiple clinical endpoints.
The strength of association of many of these markers with
clinical endpoints is remarkable: nine genes associating with all
three endpoints (FDRo0.05) after adjusting for multiple compar-
isons. Although further work needs to be done to confirm the
performance of the identified markers, a number of them are
compatible with known biology, in particular, the concept of
oncogene addiction (Weinstein, 2002). Thus, AREG and EREG,
which encode activators of the EGFR pathway, associate with
increased likelihood of clinical benefit; DUSP6, which encodes a
phosphatase inhibitor of the EGFR pathway, associates with
decreased likelihood of clinical benefit.
Although this study does not include a control arm of untreated
patients, and therefore leaves open the possibility that a number of
the described biomarkers are prognostic rather than predictive of
cetuximab benefit, it seems probable that many of the top genes
identified are in fact predictive of drug response because the
objective response endpoint lends itself to discovery of predictive
rather than prognostic biomarkers. An objective response in colon
cancer is generally recognised as a treatment effect.
We performed multivariate analysis on the entire set of
identified markers to generate a four-gene classifier that, in
exploratory analysis, performs better than EREG/AREG. Used
in conjunction with KRAS mutation status, this assay associates
with several indices of clinical outcome better than either gene
expression alone or KRAS mutation status alone.
The four-gene classifier is exploratory, as this model was
discovered and estimated using the same KRAS wt patients. The
degree of over-fitting was assessed in part through two-layer, five-
fold cross-validation. External validation of this multi-gene model
will require an independent study that is adequately statistically
powered and includes a control arm of patients who are not treated
with cetuximab.
Our findings are based on analysis of formalin-fixed primary
tumour tissue, which is generally obtained at the time of defi-
nitive colorectal tumour resection. Therefore, if this classifier
were to be validated, it will be technically feasible to introduce
it into clinical practice. The applicability of these results to
patients treated with cetuximab in combination therapy deserves
further study.
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